JP2014517313A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517313A5
JP2014517313A5 JP2014514915A JP2014514915A JP2014517313A5 JP 2014517313 A5 JP2014517313 A5 JP 2014517313A5 JP 2014514915 A JP2014514915 A JP 2014514915A JP 2014514915 A JP2014514915 A JP 2014514915A JP 2014517313 A5 JP2014517313 A5 JP 2014517313A5
Authority
JP
Japan
Prior art keywords
subject
level
risk
cardiovascular disease
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514915A
Other languages
English (en)
Japanese (ja)
Other versions
JP6059211B2 (ja
JP2014517313A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041792 external-priority patent/WO2012170974A1/en
Publication of JP2014517313A publication Critical patent/JP2014517313A/ja
Publication of JP2014517313A5 publication Critical patent/JP2014517313A5/ja
Application granted granted Critical
Publication of JP6059211B2 publication Critical patent/JP6059211B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514915A 2011-06-10 2012-06-10 サイトミックな血管健康プロファイリングのシステムおよび方法 Expired - Fee Related JP6059211B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161495955P 2011-06-10 2011-06-10
US61/495,955 2011-06-10
US201261650353P 2012-05-22 2012-05-22
US61/650,353 2012-05-22
PCT/US2012/041792 WO2012170974A1 (en) 2011-06-10 2012-06-10 System and method of cytomic vascular health profiling

Publications (3)

Publication Number Publication Date
JP2014517313A JP2014517313A (ja) 2014-07-17
JP2014517313A5 true JP2014517313A5 (https=) 2015-06-11
JP6059211B2 JP6059211B2 (ja) 2017-01-11

Family

ID=47296510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014514915A Expired - Fee Related JP6059211B2 (ja) 2011-06-10 2012-06-10 サイトミックな血管健康プロファイリングのシステムおよび方法

Country Status (7)

Country Link
US (1) US20140357505A1 (https=)
EP (1) EP2717681A4 (https=)
JP (1) JP6059211B2 (https=)
CN (1) CN104039134A (https=)
AU (1) AU2012267489B2 (https=)
CA (1) CA2838436A1 (https=)
WO (1) WO2012170974A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134791A2 (en) * 2014-03-07 2015-09-11 University Of Washington - Center For Commercialization Non-invasive biomarker of antibody-mediated allograft rejection
JP2015123503A (ja) * 2014-08-21 2015-07-06 千住金属工業株式会社 真空はんだ処理装置及びその制御方法
US20160169786A1 (en) * 2014-12-10 2016-06-16 Neogenomics Laboratories, Inc. Automated flow cytometry analysis method and system
FR3030039B1 (fr) 2014-12-12 2018-03-16 Commissariat A L'energie Atomique Et Aux Energies Alternatives Caracterisation et reproduction d'un jugement d'expert pour une classification binaire
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
BR112017022394A2 (pt) * 2015-05-07 2018-07-17 Oncoimmune Inc uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade
US20190094244A1 (en) * 2016-03-22 2019-03-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Free Functional Annexin Levels in Plasma as a Biomarker of Cardiovascular Risk
JPWO2020138351A1 (https=) * 2018-12-28 2020-07-02
CN116359488A (zh) * 2021-12-27 2023-06-30 北京积水潭医院 检测血液样本中不同类型微颗粒含量的方法
CN114674729B (zh) * 2022-03-02 2023-11-21 迈克医疗电子有限公司 脉冲识别方法、装置、存储介质、设备及血液细胞分析仪
CN120778688B (zh) * 2025-07-09 2026-04-03 广州市微米生物科技有限公司 一种流式检测试剂在肿瘤疾病的出血风险等级分类产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
WO2004045517A2 (en) * 2002-11-15 2004-06-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for the diagnosis and treatment of vascular disease
WO2005069003A1 (en) * 2003-06-27 2005-07-28 Oklahoma Medical Research Foundation Methods for predicting susceptibility to cardiovascular disease
US20050272098A1 (en) * 2004-04-23 2005-12-08 Tramontano Anthony F Quantitation of endothelial microparticles
US20060078553A1 (en) * 2004-10-07 2006-04-13 Paul Glidden Diverse multi-unit complexes including a tRNA synthetase fragment
US20100203058A1 (en) * 2009-02-11 2010-08-12 Indiana University Research And Technology Corporation Diagnostics and therapeutics based on circulating progenitor cells
JP2012531605A (ja) * 2009-07-01 2012-12-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心血管死亡率リスクを予測するための方法

Similar Documents

Publication Publication Date Title
JP2014517313A5 (https=)
Widera et al. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome
Ruparelia et al. Inflammatory processes in cardiovascular disease: a route to targeted therapies
Vogel et al. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure
Guazzi Use of TAPSE/PASP ratio in pulmonary arterial hypertension: an easy shortcut in a congested road
Dahlen et al. The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study
Donal et al. Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction
JP2015511721A5 (https=)
EP2698712A3 (en) Computer program, method, and information processing apparatus for analyzing performance of computer system
JP6059211B2 (ja) サイトミックな血管健康プロファイリングのシステムおよび方法
Tzikas et al. GDF-15 predicts cardiovascular events in acute chest pain patients
Akrawinthawong et al. Subclinical and clinical contrast-induced acute kidney injury: data from a novel blood marker for determining the risk of developing contrast-induced nephropathy (ENCINO), a prospective study
Melin et al. Variability in physical activity assessed with accelerometer is an independent predictor of mortality in CHF patients
García-Alvarez et al. Additional value of B-type natriuretic peptide on discrimination of patients at risk for mortality after a non-ST-segment elevation acute coronary syndrome
Fotiou et al. Biomarkers in AL amyloidosis
Yan et al. The prognostic impact of serum uric acid on disease severity and 5-year mortality in patients with idiopathic pulmonary artery hypertension
George et al. Evaluation of endothelial and platelet derived microparticles in patients with acute coronary syndrome
Tzouvelekis et al. S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension
Bryl-Gorecka et al. Microvesicles in plasma reflect coronary flow reserve in patients with cardiovascular disease
Boxhammer et al. Severe aortic valve stenosis and pulmonary hypertension: a systematic review of non-invasive ways of risk stratification, especially in patients undergoing transcatheter aortic valve replacement
Shantsila et al. Blood leukocytes in heart failure with preserved ejection fraction: impact on prognosis.
Zhang et al. Combining pulse wave velocity with galectin-3 to predict mortality and cerebrovascular and cardiovascular events in hemodialysis patients
Gregorić et al. Interleukin-12 as a predictor of outcome in patients with severe acute pancreatitis.
IL274279B2 (en) Predicting peptide receptor radiotherapy using a gene expression assay
Cabanas-Grandío et al. Relative performance of three formulas to assess renal function at predicting in-hospital hemorrhagic complications in an acute coronary syndrome population. What does the new CKD-EPI formula provide?